M&A Deal Summary

Pfizer Acquires GBT

On August 8, 2022, Pfizer acquired life science company GBT for 5.4B USD

Acquisition Highlights
  • This is Pfizer’s 38th transaction in the Life Science sector.
  • This is Pfizer’s 10th largest (disclosed) transaction.
  • This is Pfizer’s 30th transaction in the United States.
  • This is Pfizer’s 13th transaction in California.

M&A Deal Summary
Date 2022-08-08
Target GBT
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 5.4B USD
Advisor(s) J.P. Morgan Securities
Centerview Partners (Financial)
Cravath, Swaine & Moore
Goodwin Procter (Legal)

Target

GBT

San Francisco, California, United States
GBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 42 of 44
Sector (Life Science) 38 of 39
Type (Add-on Acquisition) 30 of 31
State (California) 13 of 14
Country (United States) 30 of 32
Year (2022) 3 of 3
Size (of disclosed) 10 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-10 Biohaven Pharmaceutical Holding

New Haven, Connecticut, United States

Biohaven Pharmaceutical Holding is a biopharmaceutical company engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. Biohaven Pharmaceutical Holding was incorporated in 2013 and is based in New Haven, Connecticut.

Buy $11.6B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-03-13 Seagen

Bothell, Washington, United States

Seagen is a biotechnology company provides an antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. Seattle was founded in 1997 and is based in Bothell, Washington.

Buy $43.0B
Mergr

Product

Company

Legal